Figure 6 | Scientific Reports

Figure 6

From: Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice

Figure 6The alternative text for this image may have been generated using AI.

Assessment of unspecific behavioural effects of CLZ in the 5-CSRTT. (a) Attentional accuracy (%); (b) relative number of omitted responses (%); (c) relative number of premature responses (%); (d) latency to collect the reward after correct responses (s); (e) latency to make a correct response after the onset of the stimulus (s); (f) number of beam breaks caused by movement between the 5-choice wall and the receptacle; (g) number of perseverative (repeated) responses into the same correct hole; and (h) total number of trials conducted by the animal within a 30-min session during the 5-CSRTT started 10 min after i.p. injection of either vehicle (Veh, black), 0.1 (yellow), 3.5 (orange) or 10 mg/kg CLZ (red), as indicated. (i) Plasma concentrations (nM) of CLZ determined 45 min after i.p. injection; statistical differences not indicated. Note that all doses were tested within one within-subject experiment, following a latin-square design in which the starting dose was counter-balanced across animals. *p < 0.05; indicated are pairwise differences assessed after a significant effect of dose in a repeated-measures ANOVA using Dunnett’s post hoc test comparing the value under a given dose of CLZ to the vehicle value. Results are shown as data from individual animals (dots) and as population mean ± s.e.m. (horizontal lines). 5-CSRTT, five-choice serial-reaction time task; ANOVA, analysis of variance; CLZ, clozapine; i.p., intraperitoneal; s.e.m., standard error of the mean.

Back to article page